Fatores bioquímicos, genéticos e clínicos implicados no déficit estatural de crianças e adolescentes com anemia falciforme
Loading...
Date
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Universidade Federal de Juiz de Fora (UFJF)
Abstract
Sickle cell anemia (SCA) is characterized by the homozygous
inheritance of a point mutation in the β chain of hemoglobin (Hb) forming an abnormal
Hb called HbS. The disease is characterized by episodes of hemolysis and vasoocclusion triggered by the deoxygenation of HbS and presents variable degrees of
organic dysfunction, which can compromise multiple organs and affect height growth
and the GH/IGF-1 axis (growth hormone/factor insulin-like growth 1). The severity of
organ dysfunction in SCA is influenced by modifying factors, which may be genetic,
including allelic variants associated with fetal hemoglobin (HbF) levels and coinheritance of alpha-thalassemia, or non-genetic, such as treatment with hydroxyurea
(HU). On the other hand, genetic factors could also influence the height of individuals
with SCA, given that studies with twins estimate the heritability of height at 90%.
Objectives: To evaluate height, bone maturation and GH/IGF-1 axis, test association
with laboratory and clinical parameters, modifying factors and genotypes of the
polymorphism in the ZBTB38 gene (rs724016) in children and adolescents with SCA.
Methods: Cross-sectional study with individuals with SCA, of both sexes and ages
ranging from 3 to 20 years, followed at the Hemocentro de Governador Valadares of
Fundação Hemominas between August 2018 and July 2019. We evaluated clinical
data collected from in-person assessment, laboratory markers collected from medical
records, bone age (BA), serum levels of IGF-1 and IGFBP-3, target height (TH)
calculated by the mean Z score (ZS) of the parents' height, ZS of adult height prediction
(AHP) calculated using IO. We define adjusted growth potential as TH subtracted from
AHP. In addition, genotyping of deletional alpha-thalassemia and the rs724016
polymorphism was performed. Results and conclusions: We evaluated 80 individuals
with SCA, 53% (43/80) male, 50% (40/80) under treatment with HU, 50.6% (40/79)
pre-pubertal, 14.1% (11/78) with co-inheritance of alpha-thalassemia and 15% (12/80)
with short stature. In multivariate evaluation, treatment with HU was associated with
higher serum levels of IGF-1 and IGFBP-3. The presence of alpha-thalassemia was
associated with lower IGF-1 levels. High HbF levels were associated with a smaller
deficit in adjusted growth potential (TH-AHP). The G variant of rs724016 was
associated with lower ZS of height (p<0.001, recessive model), in a different sense of
effect from other studies with children without SCA or another identified disease.
Additionally, the G variant of rs724016, in a dominant genetic model, was negatively
8
associated with HbF levels (p=0.016), which should be relevant for growth. A model of
the relationship between the rs724016 variant and the GH/IGF-1 axis and HbF levels
was created. We conclude that HU therapy significantly contributes to the balance of
the GH/IGF-1 axis. Furthermore, we showed that the presence of the ZBTB38 variant
rs724016 in the genotype implies shorter stature and lower HbF levels. On the other
hand, co-inheritance of alpha-thalassemia negatively affects this axis. This study
contributes with new findings regarding the height development of
children/adolescents with SCA and opens perspectives to clarify the intricate
relationship between the main known modulating factors of SCA: HbF levels and
alpha-thalassemia.
Description
Citation
Endorsement
Review
Supplemented By
Referenced By
Creative Commons license
Except where otherwise noted, this item's license is described as Acesso Aberto

